A Phase 2 Trial of the Combination of Polatuzumab Vedotin Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Mantle Cell Lymphoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Pathologically confirmed relapsed or primary refractory mantle cell lymphoma with concurrent or prior tissue sample IHC positive for cycle in D1 or that is positive for FISH or cytogenetics for t(11;14). 2) Measurable disease as defined with at least one lesion measuring > 1 x 1.5cm. 3) Negative serum pregnancy test done =7 days prior to registration, for women of childbearing potential only.

You may not be eligible for this study if the following are true:

  • 1) Pregnant women, nursing women, men or women of childbearing potential who are unwilling to employ adequate contraception. 2) Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens. 3) Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.